Tagreed Alkaltham: Fibrinogen Concentrate Is a Deliberate Clinical Choice in Acute Bleeding
Tagreed Alkaltham, Transfusion Medicine Lab Supervisor at KSMC, shared a post on LinkedIn:
“Fibrinogen concentrate is not a shortcut.
It’s a deliberate clinical choice.
In acute bleeding, fibrinogen concentrate is often discussed in terms of speed and convenience. But its real value is not how fast it can be given – it’s when and why it is given. It’s when fibrinogen deficiency is addressed, and why supporting clot stability early matters.
Fibrinogen concentrate provides a known, standardized dose, without the volume burden or preparation time associated with cryoprecipitate. In critical bleeding, knowing what to expect makes the decision safer.
It’s not that fibrinogen’s role in coagulation is unknown; the difference lies in how early it is addressed, before bleeding escalates into loss of control.
When used appropriately, it allows teams to:
- correct hypofibrinogenemia promptly
- avoid unnecessary volume overload
- and target the hemostatic deficit more precisely
From a blood bank perspective, fibrinogen concentrate represents a shift in thinking: from reactive transfusion
to intentional hemostatic management.
From a blood bank perspective, fibrinogen concentrate also offers operational clarity. It reduces pressure on cryoprecipitate stock, which is often limited, variable in availability, and time sensitive once thawed. Its longer shelf life allows for better inventory stability, without compromising readiness for true bleeding emergencies.
It requires clear protocols, shared clinical understanding, and respect for timing.
- Used thoughtfully, it strengthens care.
- Used casually, it becomes just another product.
In bleeding patients, precision is not a luxury – it is part of patient safety.Its value lies in judgment, not availability.”
Other posts featuring Tagreed Alkaltham on Hemostasis Today.
-
Jul 14, 2026, 19:35Daratumumab in Difficult-to-Treat iTTP: Updated Results from the International DarTTP Study
-
Jul 14, 2026, 17:1610 Posts Not To Miss from ISTH 2026, Part 3
-
Jul 14, 2026, 15:27Dianne E Van Der Wal: Celebrating Scientific Contributions at ISTH 2026
-
Jul 14, 2026, 15:13Alfonso Tafur: RIETE Registry Analysis Supports More Equitable Approaches to VTE Care
-
Jul 14, 2026, 15:03Heghine Khachatryan: Phase III Trial Results Support BAFF-R Inhibition in Corticosteroid-Refractory ITP
-
Jul 14, 2026, 14:51Nathan Connell: ISTH 2026 Highlights the Power of Lifelong Collaboration
-
Jul 14, 2026, 14:42Wolfgang Miesbach: VOYAGER1 Highlights Progress Toward Injection-Free Care in Hemophilia A
-
Jul 14, 2026, 12:08Elvira Grandone: Finding the Right LMWH Dose for Pregnant Patients Suffering From DVT
-
Jul 14, 2026, 12:05Eloïse Laouenan: From Washington to Paris – Join GETBO at ISTH 2026